Inactief instrument

Andere talen TapImmune Inc. OTC Bulletin Board

Aandelen

TPIV

US8760334081

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	15/05
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	15/05
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies	08/04
North American Morning Briefing : Stocks Edge -2-	27/03
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results	25/03
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	22/03
North American Morning Briefing : Markets on Hold -2-	20/03
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13/03
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601	22/01
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	22/01
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08/01
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08/01
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”	21/12
Top Midday Gainers	11/12
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	11/12
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse	11/12
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	09/11
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen TapImmune Inc. OTC Bulletin Board

Aandelen

TPIV

US8760334081

Andere talen

Filters